Davis JA - Search Results

1

Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.

Davis JA, Granger K, Sakowski A, Goodwin S, Herbst A, Smith D, Hendrickson L, Nachar VR. Davis JA, et al. Expert Rev Hematol. 2023 Jul-Dec;16(12):915-918. doi: 10.1080/17474086.2023.2285978. Epub 2023 Dec 18. Expert Rev Hematol. 2023. PMID: 37982732 No abstract available.

2

Incidence of Pneumocystis jirovecii pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis.

Davis JA, Graham A, Hendrickson L, Hess B, Gaffney K. Davis JA, et al. Leuk Lymphoma. 2022 Aug;63(8):2016-2018. doi: 10.1080/10428194.2022.2056179. Epub 2022 Mar 27. Leuk Lymphoma. 2022. PMID: 35341452 No abstract available.

3

Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.

Davis J, McGann M, Shockley A, Hashmi H. Davis J, et al. Expert Rev Hematol. 2022 Jun;15(6):473-475. doi: 10.1080/17474086.2022.2081147. Epub 2022 May 26. Expert Rev Hematol. 2022. PMID: 35603733 No abstract available.

4

Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Davis JA, Rizzieri DA, Lane AA, Taylor J, Faisal MS, Vasu S, Soong D, Li H, Herbst A, Greenwell IB. Davis JA, et al. Leuk Lymphoma. 2022 Nov;63(11):2757-2759. doi: 10.1080/10428194.2022.2090552. Epub 2022 Jun 21. Leuk Lymphoma. 2022. PMID: 35727174 No abstract available.

5

Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy.

McGann M, Davis JA, Gaffney KJ, Smith D, Edwards K, Hess BT, Hashmi H. McGann M, et al. Among authors: davis ja. Transplant Cell Ther. 2022 Sep;28(9):583-585. doi: 10.1016/j.jtct.2022.06.021. Epub 2022 Jun 30. Transplant Cell Ther. 2022. PMID: 35781100 Free article. No abstract available.

6

Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant.

Shockley A, Davis JA, Gaffney KJ, Smith D, Weeda E, Hashmi H. Shockley A, et al. Among authors: davis ja. J Oncol Pharm Pract. 2022 Oct;28(7):1613-1616. doi: 10.1177/10781552221112320. Epub 2022 Jul 5. J Oncol Pharm Pract. 2022. PMID: 35790453

7

Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.

Davis JA, Gaffney KJ, McGann M, Smith D, Edwards K, Baldino E, Bakos K, Butcher C, Greenwell B, Hess BT, Hashmi H. Davis JA, et al. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e14-e18. doi: 10.1016/j.clml.2022.09.005. Epub 2022 Oct 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36319568 Review.

8

Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies.

Davis JA, Granger K, Roubal K, Smith D, Gaffney KJ, McGann M, Cendagorta A, Thurlapati A, Herbst A, Hendrickson L, Hashmi H, Hess BT. Davis JA, et al. Blood. 2023 Jan 12;141(2):200-203. doi: 10.1182/blood.2022018283. Blood. 2023. PMID: 36332185 Free PMC article.

9

Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy.

Davis JA, Misniakiewicz J, Hendrickson L, McGann M, Herbst A, Hess BT. Davis JA, et al. Ann Hematol. 2023 Feb;102(2):461-462. doi: 10.1007/s00277-022-05045-w. Epub 2022 Nov 16. Ann Hematol. 2023. PMID: 36385650 No abstract available.

10

Organ toxicities associated with chimeric antigen receptor T-cell therapy.

McGann M, Gaffney KJ, Davis JA, Smith D, Hashmi H. McGann M, et al. Among authors: davis ja. Leuk Lymphoma. 2023 Feb;64(2):491-494. doi: 10.1080/10428194.2022.2148213. Epub 2022 Nov 23. Leuk Lymphoma. 2023. PMID: 36416619 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,056 results

Search Page

Filters